Lupin Clears USFDA Warning Letter for Goa and Pithampur Facilities

28 Jul 2023 , 10:13 AM

Lupin Limited (Lupin), a global pharmaceutical major, received correspondence from the US FDA confirming the resolution of concerns raised in the Warning Letter for its facilities in Goa and Pithampur Unit-2, Indore.

The US FDA’s evaluation of the corrective actions taken by Lupin resulted in the satisfactory resolution of the issues mentioned in the Warning Letter, which was initially issued on November 6, 2017.

Nilesh Gupta, Managing Director of Lupin, expressed his satisfaction with the positive feedback and reiterated the company’s commitment to adhering to good manufacturing practices and maintaining global quality standards for their products.

Addressing the concerns raised by regulatory authorities is crucial for pharmaceutical manufacturers to ensure the quality and safety of their products for public health.

Lupin’s proactive approach to resolving the issues highlighted in the Warning Letter showcases the company’s dedication to upholding its reputation and building consumer trust.

This milestone reaffirms Lupin’s determination to meet stringent regulatory requirements and strengthens its position in the global pharmaceutical market. The positive feedback from the US FDA marks a significant achievement for Lupin, enhancing its pursuit of excellence in providing healthcare solutions.
For feedback and suggestions, write to us at [e-mail]